Registration

PLASMA PROTEIN THERAPEUTICS ASSOCIATION for PLASMA PROTEIN THERAPEUTICS ASSOCIATION

Firm
Client
Income
—
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Medicare reimbursement relating to plasma protein therapies; Federal Medicaid and Federal drug pricing programs; FDA drug safety legislation; and follow-on biologics.

LobbyistCovered position, as disclosed
JULIE BIRKOFER New —
JOHN EDWARD GREISSING New Legal Fellow and Counsel, Senate Committee on Judiciary
JONATHAN MCKNIGHT MCKNIGHT New —

Medicare/Medicaid MMM

Medicare reimbursement relating to plasma protein therapies; Federal Medicaid and Federal drug pricing programs; FDA drug safety legislation; and follow-on biologics.

LobbyistCovered position, as disclosed
JULIE BIRKOFER New —
JOHN EDWARD GREISSING New Legal Fellow and Counsel, Senate Committee on Judiciary
JONATHAN MCKNIGHT MCKNIGHT New —

Pharmacy PHA

Medicare reimbursement relating to plasma protein therapies; Federal Medicaid and Federal drug pricing programs; FDA drug safety legislation; and follow-on biologics.

LobbyistCovered position, as disclosed
JULIE BIRKOFER New —
JOHN EDWARD GREISSING New Legal Fellow and Counsel, Senate Committee on Judiciary
JONATHAN MCKNIGHT MCKNIGHT New —

Foreign entities

Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.

EntityCountryPrincipal place of businessOwnershipContribution declared
GRIFOLS, S.A. Spain Spain 100.0% $33,000
OCTAPHARMA AG Switzerland Switzerland 100.0% $33,000

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.